AngioDynamics Gelecekteki Büyüme
Future kriter kontrolleri 3/6
AngioDynamics kazanç ve gelirinin sırasıyla yıllık 72.2% ve 5.3% oranında artması tahmin edilirken, EPS'nin yıllık 73% oranında büyümesi bekleniyor.
Anahtar bilgiler
72.2%
Kazanç büyüme oranı
72.99%
EPS büyüme oranı
| Medical Equipment kazanç büyümesi | 17.0% |
| Gelir büyüme oranı | 5.3% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 15 Jul 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Seeking Alpha • Jul 16
AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)
Summary AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum. But I downgrade to a hold as I see limited upside after the recent rally, premium valuation, and execution risk. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 05
The Market Doesn't Like What It Sees From AngioDynamics, Inc.'s (NASDAQ:ANGO) Revenues Yet
You may think that with a price-to-sales (or "P/S") ratio of 1.9x AngioDynamics, Inc. ( NASDAQ:ANGO ) is a stock worth...Analiz Makalesi • Oct 03
We Think AngioDynamics (NASDAQ:ANGO) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analiz Makalesi • Aug 26
Revenues Working Against AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 1.3x AngioDynamics, Inc. ( NASDAQ:ANGO ) is a stock worth...
Yeni Anlatı • May 30
FDA Approval And International Expansion Will Redefine Healthcare Delivery
Growth in proprietary therapies and expanding adoption of key platforms are driving improved margins, higher recurring revenues, and long-term earnings visibility.Analiz Makalesi • Jan 30
AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price Boosted 38% But Its Business Prospects Need A Lift Too
Despite an already strong run, AngioDynamics, Inc. ( NASDAQ:ANGO ) shares have been powering on, with a gain of 38% in...Seeking Alpha • Jan 16
AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares
Summary AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-digit EBITDA margins in time. Clinical data for AlphaVac and NanoKnife were positive relative to established standards of care, suggesting potentially competitive offerings in the pulmonary embolism and prostate cancer markets if management can execute. Auryon, AlphaVac, and NanoKnife all offer double-digit growth potential, but sales execution against larger entrenched rivals is not going to be easy and the Med Device business offers limited potential. Shares have surged over 60%, yet further upside toward $20 remains if management can capitalize on Med Tech opportunities. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
AngioDynamics: A Surgical Approach To Market Growth
Summary AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac showing strong performance and market acceptance. NanoKnife's FDA clearance and promising clinical trials highlight its potential in prostate cancer treatment, contributing to a 23.1% rise in disposable revenue. Despite some challenges, AngioDynamics' strategic focus on high-growth markets and a healthy balance sheet make ANGO stock a solid “Buy” for long-term growth. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 10
There Is A Reason AngioDynamics, Inc.'s (NASDAQ:ANGO) Price Is Undemanding
You may think that with a price-to-sales (or "P/S") ratio of 1.2x AngioDynamics, Inc. ( NASDAQ:ANGO ) is definitely a...Analiz Makalesi • Jul 19
AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Shareholders of AngioDynamics, Inc. ( NASDAQ:ANGO ) will be pleased this week, given that the stock price is up 13% to...Analiz Makalesi • Jul 18
Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified
The AngioDynamics, Inc. ( NASDAQ:ANGO ) share price has done very well over the last month, posting an excellent gain...Seeking Alpha • May 14
AngioDynamics: A Story To Monitor
Summary AngioDynamics, Inc. is struggling for profitability and its stock hit an all-time low of $5.26 on March 25th, 2024. However, the company is undergoing a restructuring, eliminating its manufacturing capabilities and focusing on its profitable medical technology business. Despite the challenges, the company has no debt, an increasingly higher margin portfolio, and insider buying, making its valuation potentially compelling. An analysis around AngioDynamics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Apr 09
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Summary AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a large ($2B+) and growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable AngioDynamics if products like Auryon, AlphaVac, and NanoKnife are successful. Progress toward double-digit adjusted EBITDA margins in four or five years can support a fair value of $10 today, but this is a highly speculative call. Read the full article on Seeking AlphaAnaliz Makalesi • Apr 06
AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
AngioDynamics, Inc. ( NASDAQ:ANGO ) shares have had a really impressive month, gaining 26% after a shaky period...Seeking Alpha • Jan 14
AngioDynamics: Restructuring Initiative May Not Go Far Enough
Summary AngioDynamics' latest quarter earnings missed expectations. The company is facing weaker-than-anticipated sales following the rollout of new products forcing management to revise lower full-year guidance. We expect shares to remain volatile until there is evidence of stronger growth and a path to profitability. Read the full article on Seeking AlphaAnaliz Makalesi • Oct 12
AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Despite announcing strong earnings, AngioDynamics, Inc.'s ( NASDAQ:ANGO ) stock was sluggish. Our analysis uncovered...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 5/31/2029 | 375 | 2 | -8 | 21 | 2 |
| 5/31/2028 | 355 | -13 | -8 | 10 | 3 |
| 5/31/2027 | 337 | -22 | -31 | -12 | 4 |
| 5/31/2026 | 320 | -37 | 1 | 3 | N/A |
| 2/28/2026 | 314 | -31 | 2 | 4 | N/A |
| 11/30/2025 | 307 | -28 | -9 | -6 | N/A |
| 8/31/2025 | 301 | -32 | -12 | -8 | N/A |
| 5/31/2025 | 292 | -34 | -15 | -10 | N/A |
| 2/28/2025 | 283 | -41 | -28 | -24 | N/A |
| 11/30/2024 | 286 | -225 | -30 | -23 | N/A |
| 8/31/2024 | 293 | -243 | -27 | -21 | N/A |
| 5/31/2024 | 304 | -184 | -34 | -28 | N/A |
| 2/29/2024 | 324 | -192 | -23 | -17 | N/A |
| 11/30/2023 | 330 | -14 | -7 | -3 | N/A |
| 8/31/2023 | 336 | 6 | -5 | -1 | N/A |
| 5/31/2023 | 339 | -52 | -4 | 0 | N/A |
| 2/28/2023 | 335 | -37 | -23 | -7 | N/A |
| 11/30/2022 | 328 | -33 | -33 | -17 | N/A |
| 8/31/2022 | 321 | -33 | -39 | -23 | N/A |
| 5/31/2022 | 316 | -27 | -11 | -7 | N/A |
| 2/28/2022 | 306 | -40 | -7 | -4 | N/A |
| 11/30/2021 | 303 | -38 | 7 | 11 | N/A |
| 8/31/2021 | 298 | -34 | 16 | 21 | N/A |
| 5/31/2021 | 291 | -32 | 10 | 24 | N/A |
| 2/28/2021 | 273 | -169 | 10 | 16 | N/A |
| 11/30/2020 | 271 | -171 | -14 | -8 | N/A |
| 8/31/2020 | 268 | -170 | -21 | -13 | N/A |
| 5/31/2020 | 264 | -167 | -22 | -15 | N/A |
| 2/29/2020 | 277 | -7 | N/A | 7 | N/A |
| 11/30/2019 | 273 | -6 | N/A | 33 | N/A |
| 8/31/2019 | 273 | -7 | N/A | 40 | N/A |
| 5/31/2019 | 271 | -11 | N/A | 37 | N/A |
| 2/28/2019 | 205 | -34 | N/A | 36 | N/A |
| 11/30/2018 | 223 | -16 | N/A | 32 | N/A |
| 8/31/2018 | 240 | -12 | N/A | 29 | N/A |
| 5/31/2018 | 262 | -6 | N/A | 41 | N/A |
| 2/28/2018 | 343 | 1 | N/A | 37 | N/A |
| 11/30/2017 | 345 | -10 | N/A | 47 | N/A |
| 8/31/2017 | 347 | 4 | N/A | 51 | N/A |
| 5/31/2017 | 270 | -7 | N/A | 56 | N/A |
| 2/28/2017 | 356 | -25 | N/A | 55 | N/A |
| 11/30/2016 | 358 | -27 | N/A | 53 | N/A |
| 8/31/2016 | 357 | -42 | N/A | 48 | N/A |
| 5/31/2016 | 351 | -44 | N/A | 45 | N/A |
| 2/29/2016 | 347 | -1 | N/A | 37 | N/A |
| 11/30/2015 | 346 | -6 | N/A | 37 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ANGO önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.7% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: ANGO önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: ANGO önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: ANGO şirketinin gelirinin (yıllık 5.3% ) US pazarından (yıllık 13.3% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: ANGO şirketinin gelirinin (yıllık 5.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ANGO 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/16 15:52 |
| Gün Sonu Hisse Fiyatı | 2026/09/16 00:00 |
| Kazançlar | 2026/05/31 |
| Yıllık Kazançlar | 2026/05/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
AngioDynamics, Inc. 16 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Matthew Taylor | Barclays |
| John Young | Canaccord Genuity |
| William Plovanic | Canaccord Genuity |